Drug Safety Monitoring Information
https://doi.org/10.30895/2312-7821-2020-8-2-104-106
Abstract
Experts of the Department for Evaluation of Medicinal Products’ Safety of the Scientific Centre for Expert Evaluation of Medicinal Products analysed administrative decisions of foreign regulatory authorities on the recall of medicines and/or the need to amend the prescribing information due to changes in their safety profile. The analysis helped to identify 11 administrative decisions that contain information on the following medicines registered in Russia: ranitidine, nizatidine, famotidine, pantoprazole, ondansetron, domperidone.
About the Authors
Elena V. Shubnikova
Scientific Centre for Expert Evaluation of Medicinal Products, Peoples’ Friendship University of Russia
Russian Federation
Russian Federation
Cand. Sci. (Med.).
8/2 Petrovsky Blvd, Moscow 127051
Marya A. Darmostukova
Scientific Centre for Expert Evaluation of Medicinal Products, Peoples’ Friendship University of Russia
Russian Federation
8/2 Petrovsky Blvd, Moscow 127051
Russian Federation
8/2 Petrovsky Blvd, Moscow 127051
Tatyana M. Bukatina
Scientific Centre for Expert Evaluation of Medicinal Products, Peoples’ Friendship University of Russia
Russian Federation
Russian Federation
Cand. Sci. (Med.).
8/2 Petrovsky Blvd, Moscow 127051
Review
For citations:
Drug Safety Monitoring Information. Safety and Risk of Pharmacotherapy. 2020;8(2):104-106. (In Russ.) https://doi.org/10.30895/2312-7821-2020-8-2-104-106
Views:
1390
Email this article 